Tuesday, March 03, 2009 8:25:10 PM
But both have now what a lot of biotechs have not; approved or will-be-approved drugs. So I would take the other side of your "more likely" even in these credit-squeezed times.
"dndn I think will fail."
The trial, technically ? Maybe. But clearly now after a third trial, whether the p-value is a couple of points short of or over the threshold, it is an academic argument as to whether the drug works. All that may stand between it and approval is the FDA set of "standards" (which is a lot I admit). So I think DNDN sees $6 this summer, upon a BLA filing, easy. And I would be all over it execpt for this aritifical delay. It is that close. And you know what success means.
"Yes of course idix has to deliver some goods."
And the two stocks you diss are at about the same point.
Well thanks for your feedback, it was not sarcastic at all, and we will see what happens.
"....on the biotech battle-field, you need some élan...."
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
